Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug 1;8(8):1150-1158.
doi: 10.1001/jamaoncol.2022.2228.

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial

Alexander Stein  1   2 , Lisa Paschold  3 , Joseph Tintelnot  2 , Eray Goekkurt  1   2 , Svenja-Sibylla Henkes  3 , Donjete Simnica  3 , Christoph Schultheiss  3 , Edith Willscher  3 , Marcus Bauer  4 , Claudia Wickenhauser  4 , Peter Thuss-Patience  5 , Sylvie Lorenzen  6 , Thomas Ettrich  7 , Jorge Riera-Knorrenschild  8 , Lutz Jacobasch  9 , Albrecht Kretzschmar  10 , Stefan Kubicka  11 , Salah-Eddin Al-Batran  12 , Anke Reinacher-Schick  13 , Daniel Pink  14   15 , Marianne Sinn  2 , Udo Lindig  16 , Wolfgang Hiegl  17 , Axel Hinke  18 , Susanna Hegewisch-Becker  1 , Mascha Binder  3
Affiliations
Clinical Trial

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial

Alexander Stein et al. JAMA Oncol. .

Abstract

Importance: In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations.

Objective: To investigate the efficacy of trastuzumab and PD-1 inhibitors with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors or FOLFOX in first-line treatment of advanced ERBB2-positive EGA.

Design, setting, and participants: This phase 2 multicenter, outpatient, randomized clinical trial with 2 experimental arms compared with historical control individually was conducted between March 2018 and May 2020 across 21 German sites. The reported results are based on a median follow-up of 14.3 months. Patients with previously untreated, metastatic ERBB2-positive (local immunohistochemistry score of 3+ or 2+/in situ hybridization amplification positive) EGA, adequate organ function, and eligibility for immunotherapy were included. Data analysis was performed from June to September 2021.

Interventions: Patients were randomized to trastuzumab and nivolumab (1 mg/kg × 4/240 mg for up to 12 months) in combination with mFOLFOX6 (FOLFOX arm) or ipilimumab (3 mg/kg × 4 for up to 12 weeks) (ipilimumab arm).

Main outcomes and measures: The primary end point was survival improvement with a targeted increase of the 12-month overall survival rate from 55% (trastuzumab/chemotherapy-ToGA regimen) to 70% in each arm.

Results: A total of 97 patients were enrolled, and 88 were randomized (18 women, 70 men; median [range] age, 61 [41-80] years). Baseline Eastern Cooperative Oncology Group performance status was 0 in 54 patients (61%) and 1 in 34 patients (39%); 66 patients (75%) had EGA localized in the esophagogastric junction and 22 in the stomach (25%). Central post hoc biomarker analysis (84 patients) showed PD-1 ligand 1 (PD-L1) combined positive score of 1 or greater in 59 patients (72%) and 5 or greater in 46 patients (56%) and confirmed ERBB2 positivity in 76 patients. The observed overall survival rate at 12 months was 70% (95% CI, 54%-81%) with FOLFOX and 57% (95% CI, 41%-71%) with ipilimumab. Treatment-related grade 3 or greater adverse events (AEs) and serious AEs occurred in 29 and 15 patients in the FOLFOX arm and in 20 and 17 patients in the ipilimumab arm, respectively, with a higher incidence of autoimmune-related AEs in the ipilimumab arm and neuropathy in the FOLFOX arm. Liquid biopsy analyses showed strong correlation of early cell-free DNA increase with shorter progression-free and overall survival and emergence of truncating and epitope-loss ERBB2 resistance sequence variations with trastuzumab treatment.

Conclusions and relevance: In this randomized clinical trial, trastuzumab, nivolumab, and FOLFOX showed favorable efficacy compared with historical data and trastuzumab, nivolumab, and ipilimumab in ERBB2-positive EGA. The ipilimumab arm yielded similar OS compared with the ToGA regimen.

Trial registration: ClinicalTrials.gov Identifier: NCT03409848.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Stein reported grants from Bristol Myers Squibb (BMS) during the conduct of the study; and institutional fees for advisory boards from BMS and Merck Sharp & Dohme (MSD) outside the submitted work. Dr Goekkurt reported personal fees from BMS and MSD during the conduct of the study; and personal fees from Servier, Roche, and Sanofi outside the submitted work. Dr Thuss-Patience reported personal fees (advisory board) from BMS, MSD, Merck Serono, AstraZeneca, Pfizer, Lilly, Servier, Novartis, Astellas, Roche, and Amgen outside the submitted work. Dr Ettrich reported grants from Servier, nonfinancial support from Ipsen, and personal fees from MSD, BMS, AstraZeneca, Roche, Eisai, Pierre Fabre, Merck Serono, and Bayer outside the submitted work. Dr Kretzschmar reported personal fees (lecture fees) from Roche and BMS during the conduct of the study. Prof Kubicka reported personal fees from Roche and BMS outside the submitted work. Dr Al-Batran reported grants from BMS, MSD, Sanofi, Ipsen, Roche Hospira, Lilly, Vifor Pharma, Hospira, AstraZeneca, Immutep, and Eurozyto and personal fees from Lilly, AstraZeneca, and BMS outside the submitted work. Prof Reinacher-Schick reported other (honoraria, advisory board member) from Amgen, AstraZeneca, and Pfizer; other (honoraria, travel support) from BMS; other (honoraria) from Lilly; other (honoraria, advisory board member, travel support) from Merck, MSD, and Roche; personal fees (honoraria, advisory board member, travel support) from Servier; and grants from BioNTech, Rafael, and Erytech outside the submitted work. Dr Pink reported grants from PharmaMar, Roche, Lilly, Clinigen, BMS, and EUSA Pharma and personal fees from PharmaMar, Roche, Lilly, and Blueprint Medicines outside the submitted work. Dr Sinn reported personal fees from Amgen, AstraZeneca, BMS, MSD, Sanofi, Servier, Pfizer, Incyte, Pierre Fabre, and Art Tempi outside the submitted work. Dr Lindig reported nonfinancial support, travel paid by BMS. Dr Hinke reported personal fees from German Cancer Society during the conduct of the study. Dr Binder reported grants from BMS covering the translational studies in this trial during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. CONSORT Diagram of the INTEGA Trial
Figure 2.
Figure 2.. Clinical Outcomes of Patients Treated in the INTEGA Trial
Overall (OS) (A) and progression-free survival (PFS) (B) are presented for the ipilimumab vs the FOLFOX arm. Duration of response (DOR) is shown in panel C. The waterfall plot (D) shows responses in individual patients in the intent-to-treat population (2 patients—1 in each arm—were allowed to continue in the trial based on clinical response and local treatment applied beside Response Evaluation Criteria in Solid Tumors progression). The key in panel D reports the ORRs. NA indicates not applicable; ORR, overall response rate.
Figure 3.
Figure 3.. Mutational Profiling and Liquid Biopsy Disease Monitoring
A, Percentage of patients with genes with sequence variations at baseline in liquid biopsy circulating cell-free DNA (cfDNA) and in tumor tissue. Published data of the mutational landscape of driver genes in esophageal and gastric cancer were obtained from database cBioPortal., B and C, Overall survival (OS) and progression-free survival (PFS) of patients according to the level of cfDNA in blood after the first treatment cycle (2-3 weeks) vs baseline levels. Patients with increase in cfDNA concentration of greater than 20% (n = 21) were plotted vs patients showing cfDNA reduction or stability (n = 44). P values were calculated using log-rank test. Median survival is illustrated in months (vertical dashed lines); the horizontal dashed lines indicate the median of both curves. NA indicates not applicable.
See this image and copyright information in PMC

Comment in

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. ; ToGA Trial Investigators . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X - DOI - PubMed
    1. Tabernero J, Hoff PM, Shen L, et al. . Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372-1384. doi:10.1016/S1470-2045(18)30481-9 - DOI - PubMed
    1. Janjigian YY, Shitara K, Moehler M, et al. . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2 - DOI - PMC - PubMed
    1. Sun JM, Shen L, Shah MA, et al. ; KEYNOTE-590 Investigators . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759-771. doi:10.1016/S0140-6736(21)01234-4 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources